Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma. - Wikidata - wikimedia - TriplyDB

Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma.

Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma.

http://www.wikidata.org/entity/Q34757990

about

Cytotoxic and targeted therapy for hereditary cancers Activated Alk triggers prolonged neurogenesis and Ret upregulation providing a therapeutic target in ALK-mutated neuroblastoma.Vandetanib successfully controls medullary thyroid cancer-related Cushing syndrome in an adolescent patient.Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.Growth plate abnormalities in pediatric cancer patients undergoing phase 1 anti-angiogenic therapy: a report from the Children's Oncology Group Phase I Consortium.Quantitative phosphoproteomic analysis identifies activation of the RET and IGF-1R/IR signaling pathways in neuroblastoma.Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: a pooled analysis.Diagnosis, treatment, and follow-up of medullary thyroid carcinoma: recommendations by the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism.Patterns of thyroid hormone levels in pediatric medullary thyroid carcinoma patients on vandetanib therapy.The genetic landscape of gastrointestinal stromal tumor lacking KIT and PDGFRA mutations.Pediatric Medullary Thyroid Carcinoma Milestones in the curability of pediatric cancers Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma.MicroRNA-375/SEC23A as biomarkers of the in vitro efficacy of vandetanib.The discovery and development of vandetanib for the treatment of thyroid cancer.Vandetanib for the treatment of thyroid cancer: an update.Novel therapies for thyroid cancer.Selective use of vandetanib in the treatment of thyroid cancer.Cabozantinib for the treatment of non-small cell lung cancer with KIF5B-RET fusion. An example of swift repositioning.Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer.Management of hereditary medullary thyroid carcinoma.The safety of vandetanib for the treatment of thyroid cancer.Targeted Therapies in Thyroid Cancer: An Extensive Review of the Literature.The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer.Advances in small molecule therapy for treating metastatic thyroid cancer.Personalization of targeted therapy in advanced thyroid cancer.Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib.Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes.A phosphoarray platform is capable of personalizing kinase inhibitor therapy in head and neck cancers.Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review.Medullary thyroid carcinoma - Adverse events during systemic treatment: risk-benefit ratio.Ectopic cushing in a patient with medullary thyroid carcinoma: hypercortisolism control and tumor reduction with Sunitinib.Efficacy of Vandetanib in Treating Locally Advanced or Metastatic Medullary Thyroid Carcinoma According to RECIST Criteria: A Systematic Review and Meta-Analysis.

P2860

Q26739366-1D9C34BC-DB3D-445D-901C-CED415E40EA1 Q33757079-87562295-0B35-4977-A597-BBF245AA5922 Q34131012-5B4FB9B8-01BC-4B01-9E44-FA34CE7FBC61 Q34468665-3F88928D-B05E-4D5A-ADF1-D22C2362F2C2 Q34543413-D457CAB0-85BF-4265-A8AE-71C6F2A86A8D Q35070321-7E9564F3-275C-4CB4-A8E6-F420A73EFDA5 Q35224485-0336CD8D-772E-498F-B000-7A9739D1678B Q35396089-F61E644C-4FFA-4040-BF81-7CA0DE7A5AF8 Q35599600-597922CC-6918-42C3-BE96-669FEFDA0C5F Q36509363-E31C4070-63C6-4C16-9F88-BDF3858F06F1 Q36715586-57F6D238-D295-4019-8CE8-BCB47F6ECBBD Q36925083-DBF0E9C4-86E5-4B83-A9CD-333F40D21414 Q37009001-4DA487EB-6500-451B-B8FD-CE6D32BBF565 Q37327513-81B3967A-FA54-4F97-8025-248AAFAEB9F2 Q38168304-375741DA-B288-435D-B3AC-54AF0C623560 Q38185691-CA185048-F5EF-4106-9D91-4FB74902EDF8 Q38260495-01EC54BE-C8F3-4061-93D5-CB7E605282D5 Q38546474-60F6D42B-6E75-4169-8004-A354CF84EC1B Q38588103-64F00FE7-5BFB-4809-AC84-48215B186434 Q38625034-AE626D6A-7E86-41B0-B3E0-4F05BAC74C8F Q38721033-766A247C-35AF-41A9-A1B3-A7EB6F193BF0 Q38864998-FA6F8BD1-94B6-4D5A-8B7F-72D1F9E36EAF Q38883187-A0F10C44-1984-4659-8869-361B49627CB1 Q38960074-0D5BA5AD-EF0E-43EE-ABD6-A981C7598763 Q39364787-6B1B82A2-9B52-44B9-98FC-737CE921FFD7 Q40922523-8DFCE600-6EF4-4C7A-BDD5-1BA4CDFC1827 Q47395532-5D7DC530-390C-4820-AAE4-586A80316951 Q47601932-AC120650-A3E9-40B5-989C-DE5DED2BE75E Q47804358-D6774B59-B169-40AE-ACDA-BD64754B7DE9 Q49244147-94402436-63DE-4806-9581-8A2823C4CA9B Q50918579-967E76D2-AA5C-4F46-9FCF-F498867AAAFB Q54338133-149092E2-E71A-43A6-BFDE-CA8C93DF49B1 Q54978829-E64AE619-0B73-4185-8857-5E6F7732B2F9

P2860

Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma.

http://www.wikidata.org/entity/Q34757990

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Vandetanib in children and ado ...... d medullary thyroid carcinoma.

@ast

Vandetanib in children and ado ...... d medullary thyroid carcinoma.

@en

Vandetanib in children and ado ...... d medullary thyroid carcinoma.

@nl

type

label

Vandetanib in children and ado ...... d medullary thyroid carcinoma.

@ast

Vandetanib in children and ado ...... d medullary thyroid carcinoma.

@en

Vandetanib in children and ado ...... d medullary thyroid carcinoma.

@nl

prefLabel

Vandetanib in children and ado ...... d medullary thyroid carcinoma.

@ast

Vandetanib in children and ado ...... d medullary thyroid carcinoma.

@en

Vandetanib in children and ado ...... d medullary thyroid carcinoma.

@nl

P1433

Q34757990-D1B018DB-1C8F-46B1-8786-7CF288797B15

P1476

Q34757990-B42F2F75-F00D-4A28-AC63-D643D1C96C40

P2093

Q34757990-01B4C42C-9679-4766-9E2B-8A014B8271B5

Q34757990-5C0F256F-15C0-44C2-8F8A-CD6358F1380D

Q34757990-802A3DDF-2FDB-4F51-8969-D1DCBA40E7C1

Q34757990-AA78EC52-F008-4ED6-98EE-4E1B3BB2AAC7

Q34757990-AB1ABF67-DCAA-4124-9BA4-DA5DDCCE8642

Q34757990-C69498EC-3075-49E8-A4EB-E1323991A4DB

Q34757990-D9C43681-4448-419D-8E01-5EBAFA5E6DA3

Q34757990-E01939BF-5523-4D5F-BF28-9D88A97F6073

Q34757990-E757F171-EECB-44A6-9BAE-F36461078E85

Q34757990-E7ED8A73-5B08-4DF5-89FE-B8AB1A2FBD52

P2860

Q34757990-009794A0-98A0-48E6-95C0-808A6053696D

Q34757990-0F5041FC-949F-4961-AA43-FABFA0B58C62

Q34757990-13DE8AAA-A632-43BE-83BB-91AD859BE557

Q34757990-2524CFC7-8F96-4F60-9812-A0CEDF2EFA71

Q34757990-327F7674-EBA6-432C-BFAD-DAD36DD5AF75

Q34757990-3BFC395E-69A8-4097-AF2B-E8A820FEA8A6

Q34757990-46D2EAFF-2F83-4169-B4E7-2EC7AB5A9A2A

Q34757990-4CA79199-CFEF-4F47-AEA7-9E33E796CD00

Q34757990-4DC2471C-AB05-44AD-9644-33FF57F4113B

Q34757990-56AB5513-2557-4A13-88A1-DA7C12999A46

P304

Q34757990-E13967A7-3339-4B0F-820F-6476F65E5677

P31

Q34757990-AC4696F9-52A2-4D4A-AA7B-36A2CFB9FCAE

P356

Q34757990-CD23DB56-AE70-4286-A679-85EB74370EE0

P407

Q34757990-FDC269AD-3FF7-4081-888D-AB6EA0DAC720

P433

Q34757990-9688CDBF-8D51-4ED7-AC20-52B4FC4A7772

P478

Q34757990-91CD0C27-1DBE-4E3F-9139-8C41616954E8

P577

Q34757990-5D591D29-E9C9-41C4-BD36-311E313FAC68

P698

Q34757990-3D9A1729-676F-4992-9502-3F0283086BBF

P921

Q34757990-5389CEF4-DCB5-48B4-AA3E-D78D8B7540E2

P932

Q34757990-E7DCE1CB-1BAC-4196-AFE9-C754D7D2A069

P356

1078-0432.CCR-13-0071

P1433

Clinical Cancer Research

P1476

Vandetanib in children and ado ...... d medullary thyroid carcinoma.

@en

P2093

Alberta Aikin

http://www.w3.org/2001/XMLSchema#string

Brigitte C Widemann

http://www.w3.org/2001/XMLSchema#string

Elizabeth Fox

http://www.w3.org/2001/XMLSchema#string

Eva Dombi

http://www.w3.org/2001/XMLSchema#string

Frank M Balis

http://www.w3.org/2001/XMLSchema#string

Leigh Marcus

http://www.w3.org/2001/XMLSchema#string

Maria J Merino

http://www.w3.org/2001/XMLSchema#string

Maya Lodish

http://www.w3.org/2001/XMLSchema#string

Meredith K Chuk

http://www.w3.org/2001/XMLSchema#string

Patricia O Whitcomb

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B

Clinical relevance of RET variants G691S, L769L, S836S and S904S to sporadic medullary thyroid cancer.

The thyroid and the gut.

Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.

Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer

Guidelines for diagnosis and therapy of MEN type 1 and type 2.

ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.

Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.

A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors.

P304

4239-4248

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-13-0071

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P577

2013-06-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23766359

http://www.w3.org/2001/XMLSchema#string

P921

P932

4274128

http://www.w3.org/2001/XMLSchema#string